XELLIA PHARMACEUTICALS ApS: Financial statements 2019
CVR: 61094628
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 2,346,296,000 and a net result of DKK 390,722,000 compared with DKK -74,912,000 the year before. That is an increase of 24.1% compared with the year before. The profit margin was 16.7%. Equity in the 2019 report amounted to DKK 1,391,325,000. The solvency ratio was 52.5%. The company had 623 employees in the financial year.
- Revenue
- DKK 2,346,296,000
- Gross Profit
- DKK 873,518,000
- Profit/Loss
- DKK 390,722,000
- Equity
- DKK 1,391,325,000
- Total Assets
- DKK 2,651,568,000
- Employees
- 623
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 2.3B | 873.5M | 390.7M | 1.4B | 623 |
| 2018 | 1.9B | 576.7M | -74.9M | 1B | 580 |
| 2017 | 1.9B | 528.3M | 91M | 850.8M | 493 |
| 2016 | 1.5B | 521.8M | 33.8M | 758.8M | 466 |
| 2015 | 1.2B | 364.2M | -74M | 729.2M | 479 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
XELLIA PHARMACEUTICALS ApS has published its annual report for 2018. Revenue came to DKK 1,890,464,000, and the net result was DKK -74,912,000.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.